Dell Technologies Inc vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? Dell Technologies Inc trades at $586.28 (market cap $365.31B), while Iovance Biotherapeutics Inc. Common Stock trades at $14.63 (market cap $6.04B). The key difference: Dell Technologies Inc is far larger — about 60.5× Iovance Biotherapeutics Inc. Common Stock's market cap, and Dell Technologies Inc pays a 0.44% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dell Technologies Inc for 57 Days and Iovance Biotherapeutics Inc. Common Stock for 0 Days on average.
| DELL | IOVA | |
|---|---|---|
Market Cap | $365.31B | $6.04B |
Volume | 5,121,365 | 14,805,993 |
Sector | Technology | Health |
52-Week High | $588.67 | $14.82 |
52-Week Low | $111.10 | $1.81 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | $388.20B | $5.97B |
Dividend Yield | 0.44% | — |
Signals from Pluang's Aura AI — not financial advice
Dell Technologies (DELL) trades at $586.28, up 1.26% today, with a bullish technical outlook as the price hovers near resistance at $585. Recent earnings beats, including Q2 2026 EPS of $7.04 versus $4.91 expected, and a raised AI server revenue forecast to $74 billion for fiscal 2027 highlight strong operational momentum. The stock's valuation reflects growth expectations with a P/E of 33.42 and P/S of 2.52.
The outlook remains positive driven by AI server demand, but risks include high valuation sensitivity and competitive pressures. Analyst consensus is bullish with a $566.35 price target, though the current price exceeds this, suggesting near-term consolidation may precede further gains if execution continues.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses
Read more on DELL →Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →